Molecular Formula | C27H29N5O3
|
Molar Mass | 471.55 |
Density | 1.33±0.1 g/cm3(Predicted) |
Boling Point | 713.4±60.0 °C(Predicted) |
pKa | 15.35±0.40(Predicted) |
Storage Condition | 2-8℃ |
Physical and Chemical Properties | Bioactive Zanubrutinib (BGB-3111) is an effective and specific irreversible BTK inhibitor, which has only weak off-target inhibitory effect on other kinases such as ITK, JAK3 and EGFR. |
In vitro study | In biochemical and cellular experiments, BGB-3111 was more selective for BTK than ibrutinib. In several MCL and DLBCL cell lines, BGB-3111 inhibited BTK autophosphorylation induced by BCR aggregation, inhibited downstream PLC-γ2 signaling, and cell proliferation. |
In vivo study | In preclinical animal experiments, BGB-311 had good oral bioavailability, higher exposure and more complete target inhibition in tissues than ibrutinib. In the mouse BTK occupancy assay, BGB-3111 could occupy BTK in a concentration-dependent manner, binding to BTK in target organs (e. G., PBMC and spleen) was more than 3 times greater than ibrutinib. In REC-1 MCL and ABC subtype DLBCL (TMD-8) xenograft tumor models, BGB-3111 can induce concentration-dependent anti-tumor effect, which is better than ibrutinib. In a drug toxicity analysis performed in rats, BGB-3111 was well tolerated and the dose of 250 mg/kg/day did not reach its maximum tolerated dose. |